The Medical Research Council has reopened curiosity-driven funding after a pause, setting out a new model designed to speed decisions, widen participation in assessment and support more cross-disciplinary medical science across the UK.
Funding restarts with a broader, more flexible structure
In a statement published on 13 March 2026, the MRC said applicant-led funding opportunities would reopen on 7 April, while experimental medicine opportunities would open on 30 April. The council said the redesign is intended to strengthen support for discovery research that advances understanding of human disease mechanisms and helps enable precision prevention, early diagnosis and treatment. MRC announcement
Professor Patrick Chinnery, the MRC Executive Chair, said the pause had given the council time to reform its funding process so it better reflects current research questions. He said the organisation’s mission is to advance knowledge, improve lives and drive growth through support for curiosity-driven research.
New College of Experts to shape assessments
Under the redesigned approach, MRC said it will bring together its existing applicant-led research funding boards into a single College of Experts. The council said this new structure will retain the full breadth of its remit, from molecules to cells, tissues and organs, physiological systems and human populations.
MRC added that funding panels will be drawn flexibly from the College of Experts and will scrutinise all applications received. The council said the changes are intended to let researchers shape the assessment process, enable quicker decisions for many applicants, and increase opportunities for researchers to take part in panel assessment.
What the new timetable means for applicants
The council said applicant-led funding opportunities will remain open all year, with funding decisions made twice a year in June and December. Its first application shortlisting in 2026 is scheduled for July, with decisions planned for December. The MRC also said early career researchers will be particularly supported.
The funding timetable published alongside the announcement includes reopening dates for several opportunities in 2026, including the pre-clinical translational models hub, applicant-led research grants, NHS patient flow dementia challenge and experimental medicine calls. The council also said translation and commercialisation schemes will reopen in July 2026 under updated names.
Implications for UK medical research
The move comes as the MRC seeks to improve the way it supports high-risk, high-reward research across biomedical and health sciences. For UK researchers, the changes may matter well beyond the funding calendar: they signal a shift toward a more integrated system that rewards interdisciplinary work and aims to move promising ideas through to clinical and translational impact.
While the council said it will monitor the impact of the new approach to make sure it delivers its ambitions, the reopening itself marks an important step for a research community that depends on stable access to competitive funding. For laboratories, clinical teams and translational researchers across the UK, the return of applicant-led opportunities is likely to be welcomed as a sign that the funding pipeline is moving again.
